AAPL   319.22 (+0.30%)
MSFT   182.18 (+0.43%)
FB   224.87 (-0.26%)
GOOGL   1,428.04 (+0.69%)
AMZN   2,409.91 (+0.26%)
NVDA   345.64 (+1.81%)
CGC   17.77 (-18.11%)
BABA   198.59 (-0.45%)
MU   47.42 (+2.04%)
GE   6.55 (-3.54%)
TSLA   819.99 (+1.76%)
AMD   52.66 (+1.76%)
T   30.55 (-1.64%)
ACB   14.07 (-8.28%)
F   5.64 (-3.75%)
GILD   75.17 (-0.20%)
NFLX   413.65 (+0.05%)
BA   144.40 (-3.62%)
AAPL   319.22 (+0.30%)
MSFT   182.18 (+0.43%)
FB   224.87 (-0.26%)
GOOGL   1,428.04 (+0.69%)
AMZN   2,409.91 (+0.26%)
NVDA   345.64 (+1.81%)
CGC   17.77 (-18.11%)
BABA   198.59 (-0.45%)
MU   47.42 (+2.04%)
GE   6.55 (-3.54%)
TSLA   819.99 (+1.76%)
AMD   52.66 (+1.76%)
T   30.55 (-1.64%)
ACB   14.07 (-8.28%)
F   5.64 (-3.75%)
GILD   75.17 (-0.20%)
NFLX   413.65 (+0.05%)
BA   144.40 (-3.62%)
AAPL   319.22 (+0.30%)
MSFT   182.18 (+0.43%)
FB   224.87 (-0.26%)
GOOGL   1,428.04 (+0.69%)
AMZN   2,409.91 (+0.26%)
NVDA   345.64 (+1.81%)
CGC   17.77 (-18.11%)
BABA   198.59 (-0.45%)
MU   47.42 (+2.04%)
GE   6.55 (-3.54%)
TSLA   819.99 (+1.76%)
AMD   52.66 (+1.76%)
T   30.55 (-1.64%)
ACB   14.07 (-8.28%)
F   5.64 (-3.75%)
GILD   75.17 (-0.20%)
NFLX   413.65 (+0.05%)
BA   144.40 (-3.62%)
AAPL   319.22 (+0.30%)
MSFT   182.18 (+0.43%)
FB   224.87 (-0.26%)
GOOGL   1,428.04 (+0.69%)
AMZN   2,409.91 (+0.26%)
NVDA   345.64 (+1.81%)
CGC   17.77 (-18.11%)
BABA   198.59 (-0.45%)
MU   47.42 (+2.04%)
GE   6.55 (-3.54%)
TSLA   819.99 (+1.76%)
AMD   52.66 (+1.76%)
T   30.55 (-1.64%)
ACB   14.07 (-8.28%)
F   5.64 (-3.75%)
GILD   75.17 (-0.20%)
NFLX   413.65 (+0.05%)
BA   144.40 (-3.62%)
Log in

NASDAQ:IMRNIMMURON LTD/S Stock Price, Forecast & News

$2.10
-0.10 (-4.55 %)
(As of 05/29/2020 01:14 PM ET)
Add
Compare
Today's Range
$2.10
Now: $2.10
$2.28
50-Day Range
$1.60
MA: $2.23
$3.20
52-Week Range
$1.55
Now: $2.10
$7.25
Volume3,117 shs
Average Volume6,238 shs
Market Capitalization$7.52 million
P/E RatioN/A
Dividend YieldN/A
Beta2.58
Immuron Limited, a biopharmaceutical company, focuses on the research and development of immunomodulatory polyclonal antibodies for the treatment and prevention of various diseases through its oral immunoglobulins platform in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company markets Travelan for the prevention of travelers' diarrhea. Its lead product candidate IMM-124E is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease. The company is also developing IMM-529, a clinical stage product for clostridium difficile infections. The company has a research and development collaboration agreement with the Walter Reed Army Institute of Research to develop a vaccine for a form of dysentery; and US Naval Medical Research Center to test the reactivity and therapeutic effectiveness of Travelan against Campylobacter and enterotoxigenic escherichia coli. Immuron Limited was founded in 1994 and is headquartered in Carlton, Australia.
Read More
IMMURON LTD/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IMRN
CUSIPN/A
CIKN/A
Phone610398245254

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.71 million
Book Value$1.47 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$7.52 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter.

IMMURON LTD/S (NASDAQ:IMRN) Frequently Asked Questions

How has IMMURON LTD/S's stock been impacted by COVID-19 (Coronavirus)?

IMMURON LTD/S's stock was trading at $2.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IMRN shares have decreased by 19.2% and is now trading at $2.10. View which stocks have been most impacted by Coronavirus.

Has IMMURON LTD/S been receiving favorable news coverage?

News articles about IMRN stock have been trending positive on Friday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. IMMURON LTD/S earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutIMMURON LTD/S.

Who are some of IMMURON LTD/S's key competitors?

What other stocks do shareholders of IMMURON LTD/S own?

Who are IMMURON LTD/S's key executives?

IMMURON LTD/S's management team includes the following people:
  • Mr. Peter Anastasiou, Exec. Vice Chairman (Age 59)
  • Dr. Jerry Kanellos Ph.D., Chief Operating Officer (Age 58)
  • Dr. Gary S. Jacob, CEO & Director (Age 72)
  • Mr. Phillip Allen Hains, CFO & Company Sec. (Age 60)
  • Mr. David Lyon, Head of Marketing

When did IMMURON LTD/S IPO?

(IMRN) raised $6 million in an IPO on Friday, June 9th 2017. The company issued 600,000 shares at a price of $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) acted as the underwriters for the IPO and WallachBeth Capital was co-manager.

What is IMMURON LTD/S's stock symbol?

IMMURON LTD/S trades on the NASDAQ under the ticker symbol "IMRN."

How do I buy shares of IMMURON LTD/S?

Shares of IMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IMMURON LTD/S's stock price today?

One share of IMRN stock can currently be purchased for approximately $2.10.

How big of a company is IMMURON LTD/S?

IMMURON LTD/S has a market capitalization of $7.52 million and generates $1.71 million in revenue each year.

What is IMMURON LTD/S's official website?

The official website for IMMURON LTD/S is www.immuron.com.au.

How can I contact IMMURON LTD/S?

IMMURON LTD/S's mailing address is 62 LYGON STREET LEVEL 3, CARLTON C3, 3053. The company can be reached via phone at 610398245254 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.